MLH1启动子高甲基化子宫内膜癌的生存结局:一项系统综述与荟萃分析
该系统综述与荟萃分析检索5个文献数据库和3个临床试验注册库至2025年1月10日,纳入11项队列研究共3980例错配修复缺陷(MMRd)子宫内膜癌患者,比较MLH1启动子高甲基化(MLH1ph)与非MLH1ph MMRd患者的生存结局。随机效应荟萃分析显示,MLH1ph患者死亡风险(OS HR 1.34,95%CI 1.16-1.56)和疾病进展或死亡风险(PFS HR 1.33,95%CI 1.12-1.58)显著高于非MLH1ph MMRd患者。
要点
- MLH1ph子宫内膜癌占MMRd子宫内膜癌的80%(3176/3980例)。
- MLH1ph患者OS HR 1.34(95%CI 1.16-1.56),死亡风险显著高于非MLH1ph MMRd患者。
- MLH1ph患者PFS HR 1.33(95%CI 1.12-1.58),疾病进展或死亡风险显著高于非MLH1ph MMRd患者。
核心结论
- MLH1ph子宫内膜癌是生存结局显著更差的高危分子亚组。
- 作者认为,当检测到MLH1/PMS2蛋白缺失时应常规进行MLH1ph检测。
- 作者认为,提高对该亚组的识别有助于完善分子风险分层,并实现更个体化、更有效的肿瘤管理策略。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南。
- 检索5个文献数据库和3个临床试验注册库,检索时间从建库至2025年1月10日。
- 纳入随机/准随机临床试验及前瞻性或回顾性队列研究,评估MLH1ph子宫内膜癌与非MLH1ph MMRd子宫内膜癌的OS或PFS。
- 共纳入11项队列研究(2007—2023年),来自6个国家,合计3980例MMRd子宫内膜癌患者,其中MLH1ph 3176例(80%),非MLH1ph MMRd 804例(20%)。
- OS荟萃分析纳入8项研究(n=2524),PFS荟萃分析纳入9项研究(n=1968);数据由两名作者独立提取,采用固定效应和随机效应模型估计合并HR,并使用纽卡斯尔-渥太华量表评估偏倚风险。
主要发现
- 随机效应荟萃分析显示,MLH1ph子宫内膜癌患者死亡风险显著高于非MLH1ph MMRd患者(OS HR 1.34,95%CI 1.16-1.56)。
- 随机效应荟萃分析显示,MLH1ph子宫内膜癌患者疾病进展或死亡风险显著高于非MLH1ph MMRd患者(PFS HR 1.33,95%CI 1.12-1.58)。
关键数值与推荐
- OS合并HR为1.34(95%CI 1.16-1.56),比较MLH1ph与非MLH1ph MMRd子宫内膜癌。
- PFS合并HR为1.33(95%CI 1.12-1.58),比较MLH1ph与非MLH1ph MMRd子宫内膜癌。
临床怎么用
- 作者认为,当检测到MLH1/PMS2蛋白缺失时应常规进行MLH1ph检测。
- 作者认为,提高对该亚组的识别有助于完善分子风险分层,并实现更个体化、更有效的肿瘤管理策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mismatch repair deficient (MMRd) endometrial carcinomas (EC) constitute 30 % of ECs and emerging evidence suggests that MLH1 promoter hypermethylated (MLH1ph) tumours may be more aggressive than previously recognized. This study aimed to evaluate overall survival (OS) and progression-free survival (PFS) in MLH1ph ECs compared to non-MLH1ph MMRd ECs. DESIGN: A systematic review and meta-analysis was conducted following PRISMA guidelines. Five bibliographic databases and three clinical trial registries were searched from inception to January 10, 2025. Eligible studies included randomized/quasi-randomized clinical trials and prospective/retrospective cohort studies evaluating OS or PFS in MLH1ph ECs versus non-MLH1ph MMRd ECs. Data were extracted independently by two authors. Fixed-effect and random-effects meta-analyses estimated pooled HRs, and risk of bias was assessed using the Newcastle-Ottawa Scale. RESULTS: Of 15,659 studies identified, 11 cohort studies (2007-2023) from six countries included 3980 MMRd EC patients (3176 MLH1ph cases [80 %] and 804 non-MLH1ph MMRd cases [20 %]). Eight studies (n = 2524) were included in the OS meta-analysis and nine studies (n = 1968) in the PFS meta-analysis. Random-effects meta-analyses demonstrated significantly higher risk of (1) death (OS HR 1.34, 95 %CI 1.16-1.56) and (2) disease progression or death (PFS HR 1.33, 95 %CI 1.12-1.58) in MLH1ph ECs compared to non-MLH1ph MMRd ECs. CONCLUSIONS: MLH1ph ECs represent a higher-risk molecular subgroup with significantly poorer survival. Our findings support routine MLH1ph testing when MLH1/PMS2 protein loss is identified. Improved recognition of this subgroup is crucial for refining molecular risk stratification and will enable more personalized and effective oncologic management strategies based on tumour biology.
引用
- Lim JW, Drost L, Fazelzad R, et al. MLH1 promoter hypermethylated endometrial cancer survival outcomes: A systematic review and meta-analysis. Gynecol Oncol. 2025. PMID: 41389786. doi:10.1016/j.ygyno.2025.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。